Background: We sought to identify clinical associations and potential triggers of Guillain-Barré syndrome (GBS) within 8 weeks of surgical procedures. Methods:
P atients with Guillain-Barré syndrome (GBS) may recall a flu-like syndrome weeks before the onset of symptoms. Other antecedent events have been reported, including trauma, vaccination, blood transfusion, administration of chemotherapy, or surgery. Two publications from Mayo Clinic and Massachusetts General Hospital have reported surgical procedures as a trigger for GBS. 1, 2 Since these observations were published, 2 retrospective series noted an incidence of GBS after surgery of 5% and 9.5%, and multiple subsequent case reports have been published, most commonly in patients undergoing cardiovascular, gastrointestinal, or neurosurgical procedures. [1] [2] [3] [4] [5] [6] [7] [8] The first detailed study on postoperative polyneuritis reported that postsurgical GBS occurred as a result of the release of nerve antigen during the course of surgery. Further, the authors hypothesized an association with other host factors that caused a vigorous immunologic response, culminating in the development of polyneuritis. 1 Others have postulated that surgical stress induced the activation of neuroendocrine stress axis and cell-mediated immunosuppression, which in turn might promote infections resulting in the production of cross-reactive antibodies. 9, 10 We aimed to understand whether patients who presented with GBS within 8 weeks of undergoing a surgery or procedure are different from other patients developing GBS.
METHODS
We retrospectively reviewed medical records of patients diagnosed with GBS between January 1995 and June 2014 at Mayo Clinic. We used the search terms acute demyelinating polyneuropathy, Guillain-Barré syndrome, and Miller Fisher syndrome in the reason for admission, discharge diagnosis, body of the clinical documents, and problem list to identify patients. All charts were reviewed and only patients aged 18-90 years with GBS diagnosed on the basis of diagnostic criteria proposed in 1990 (figure 1) were included. 11 We excluded patients who Patients with postsurgical GBS were compared with those with GBS and no prior surgery/ procedure to determine the differences between groups.
were diagnosed with GBS outside Mayo Clinic or were experiencing a recurrent episode of GBS.
Variables collected included basic demographics, history of autoimmune disorders and malignancy, other established GBS triggers, surgery/procedure type, type of anesthesia, number of days from the surgery/procedure to onset of GBS, details of treatment for the GBS episode, duration of hospital stay, and recurrence of GBS during follow-up. Active malignancy was defined as a diagnosis of cancer within 6 months of enrollment, any treatment for cancer within the previous 6 months, or documented recurrent or metastatic cancer. 12 The study group was defined as those patients who developed postsurgical GBS, defined as GBS symptom onset within 8 weeks of a surgery or procedure. 3 Patients with postsurgical GBS were compared with those with GBS and no prior surgery/procedure to determine the differences between groups.
Standard protocol approvals, registrations, and patient consents This study was reviewed by and received approval from our institutional review board. Patients who had not given consent to use their medical records for research were excluded.
Statistical analysis
Descriptive summaries were reported using frequencies and percentages for categorical variables and median and interquartile range (IQR) for continuous variables. Statistical significance was set at the conventional 2-tailed a level of 0.05. Associations between the categorical variables were assessed using the x 2 test or Fisher exact test as appropriate and Kruskal-Wallis test was used to compare the continuous variables as they were not normally distributed. Further analysis was performed using the multivariate logistic regression. Variables with p values of ,0.05 were considered as candidate variables for multivariate regression. Since only 3 variables could be analyzed simultaneously in the model (due to small size of the population and to avoid overfitting), multiple models with all possible combinations of important variables were analyzed, before arriving at the final set of included variables. Odds ratio and 95% confidence intervals were used to quantify the strength of associations. All the statistical analyses were performed using JMP 10.0.0 (SAS Institute Inc., Cary, NC).
RESULTS
We identified 969 patients using our search terms, 208 of whom met inclusion criteria (figure 2). Median age was 55 years (IQR 41-68), and 120 (58%) were men. The demographic details are presented in table 1. Thirty-one (15%) patients developed postsurgical GBS. The median age of patients with postsurgical GBS was 63 years (IQR 57-71) and 20 (65%) were men. Details of the surgeries and procedures are included in table 2. The most commonly used type of anesthesia was general in 18 (52%) patients, followed by conscious sedation in 13 (41.9%) patients. No patient developed GBS after a procedure in which they were administered only spinal or local anesthesia. The median duration from the surgery or procedure to the onset of GBS symptoms was 19 days (IQR 11-38).
Nineteen (61%) patients had an associated malignancy and 10 patients (52.6%) had active malignancies. Gastrointestinal (5; 26%) and hematologic malignancies (5; 26%) were the most common type, followed by prostate (3; 16%) and gynecologic cancer (3; 16%). Comorbid
Patients with postsurgical GBS were more likely to have comorbid autoimmune conditions compared to those who developed GBS without a prior surgery.
Neurology.org/cp autoimmune conditions were present in 9 (29%) patients with postsurgical GBS. Apart from surgical procedures, other triggers were identified in 11 (36%) patients, including chemotherapy in 5 (45%), blood transfusion in 4 (35%), and trauma and vaccination in 2 (7%) patients each. Twenty (65%) patients were treated with IV immunoglobulin (IVIg), 8 (26%) with plasmapheresis, and 2 (7%) received both IVIg and plasmapheresis. The median duration of hospital stay was 12 days (IQR 6-19). Five (16%) patients died during the hospital stay. The cause of death is unknown in 2 patients, related to underling malignancy in 2 patients, and related to respiratory failure due to pneumonia in 1 patient. The median duration of followup after the diagnosis was 42 months (IQR 2-123). Sixteen patients underwent surgical procedures after the diagnosis of GBS and the median number of surgical procedures was 1 (IQR 0-2). There were no recurrences of GBS in these patients. On univariate analysis, the factors that were associated with GBS after a surgery or procedure were age (p 5 0.003), malignancy (p , 0.0001), active malignancy (p 5 0.05), or preexisting autoimmune disorder (p 5 0.001) (table 3). On multivariate logistic regression analysis, age (p 5 0.05), malignancy (p , 0.0001), and preexisting autoimmune disorder (p 5 0.004) remained significant (table 4) .
DISCUSSION
In this large consecutive series of patients with GBS, we found that malignancy and comorbid autoimmune disease were strongly and independently associated with the development of postsurgical GBS, while older age was less strongly associated.
A positive history of autoimmune conditions was present in nearly 10% of the patients with postsurgical GBS in our series. Patients with postsurgical GBS were more likely to have comorbid autoimmune conditions compared to those who developed GBS without a prior surgery. Existing literature with regard to adult populations reported autoimmune conditions to be more prevalent in patients with GBS, accounting for 10%-14%. This finding was consistent with the results of the present study and higher than the incidence of autoimmune disorders in the population at large. 13, 14 This might be attributed to the transient immunosuppression, which in turn caused an inflammatory response to the neurogenic protein in the peripheral Thoracic surgery 3 (9.6)
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Oral maxillofacial surgery 1 (3.2) nervous system (PNS), thereby triggering GBS. 15 Multiple previously published case reports have documented the association between GBS and immunodeficiency and malignancy. [16] [17] [18] [19] [20] [21] A population-based study in patients with GBS concluded that cancer patients were more prone to develop GBS, with a reported prevalence of 2.4 times higher when compared to the general population. 19 Interestingly, comorbid malignancy was an independent risk factor for the development of postsurgical GBS in the present study when compared to the control group. Still, there is no consensus about the association between postsurgical GBS and malignancy or preexisting autoimmune disease. We presumed that the surgical procedure caused exposure of nerve roots, followed by oncoantigen-mediated misdirection of autoimmune response to epitopes present in the PNS. 19 The other possibility considered was immune dysregulation secondary to the pharmacologic agents (e.g., halothane, enflurane, propofol, ketamine) used during the last few decades. Most of these drugs were lipid soluble and could interact with PNS myelin and initiate the cascade of immunologic process. Such lipid-soluble drugs and trauma to the nerve root could cause demyelinating disorders in the setting of transient immunosuppression. 13 A third possibility is immunosuppression triggering GBS, secondary to surgical procedure, underlying malignancy, or subclinical infections.
Other factors known to be associated with GBS include transplantation, Hodgkin disease, leukemia, infection, vaccination, and blood transfusion. [16] [17] [18] [19] [20] [21] Our study population was comparable to previously published series with respect to the distribution of other triggering factors.
During the study period, more than 50,000 surgeries were performed under general anesthesia and innumerable procedures were performed under conscious sedation at the institution where the study was undertaken. The occurrence of GBS after a surgery or procedure was therefore extremely rare and this was demonstrated earlier in large population studies. 3, 4, 22 A surgery or procedure preceded the onset of GBS symptoms in 15% of patients in the present study, conducted over 18.5 years. In the Massachusetts General Hospital, a series of 169 patients with GBS was observed from 1962 to 1978. About 10 patients with postsurgical GBS were reported with postoperative wound infections or blood transfusions, and one patient with cytomegalovirus infection. The findings of the present study were higher than what was previously reported with smaller study populations. [3] [4] [5] 22 One study reported an incidence of postsurgical GBS of 9.5%. Within a relatively small cohort of 63 patients, 6 patients developed GBS within 6 weeks of a surgery. The affected group included patients with exposure to general anesthesia during the surgical procedure only. 4 We included a large series of 208 patients who underwent both general and conscious sedation. Traditionally, most of the procedures were done under general anesthesia. However, over the last 2 decades, due to advances in surgical techniques and anesthetic medications, higher prevalence of side effects associated with general anesthesia, and endotracheal intubation, most procedures such as colonoscopy, endotracheal biopsy, and laparoscopic surgeries were performed under conscious sedation. [23] [24] [25] [26] We presumed that the risk of nerve damage associated with procedures and transient immunosuppression remained the same, regardless of the duration of procedure and type of anesthetic medications used. In addition, we included patients with symptom onset within 8 weeks from the onset of a surgical procedure. These 2 factors probably accounted for the higher incidence of postsurgical GBS in the current study. In another study, including pediatric and adult patients, 1,034 patients developed GBS during the study period, among whom 52 (5%) experienced symptom onset within 8 weeks of a surgical procedure. 3 In the abovementioned study, patients with other potential triggering factors for GBS occurring within 8 weeks of symptom onset were not excluded. This aspect was similar to the present study.
Mortality rate was 16% among patients with postsurgical GBS. Deaths were predominantly noticed during the acute and early plateau phase. Mortality was shown to be higher in cancer patients who developed GBS when compared to the general population. 19 In an earlier study involving a large series of patients with GBS, the mortality rate was 2.8%-3.9% at 1 year follow-up. It was also observed that death occurred predominantly during the recovery phase. 27 We attributed this to the preexisting comorbid conditions and complications of the surgical procedures in these patients, since the mortality rate for the entire GBS series, including patients without an antecedent surgical procedure, was 2.4%.
The duration of hospital stay in patients with GBS after the surgical procedure was found to be longer when compared to that in patients who did not undergo surgery. This might be due to the time required for postoperative recovery. However, future studies should examine if the course of GBS would be more severe and prolonged in patients with antecedent surgery than without.
We were not able to document the incidence and attributable risk in the study population without an exact number of surgical procedures performed during the study period. Nonetheless, patients developing GBS after a surgery or procedure represent a rare, distinct cohort with more frequent history of malignancy and autoimmunity.
Surgical procedures antedated GBS in 15% of patients, which was unexpectedly high. In most instances, surgery does not predispose patients to new onset of quadriparesis within 8 weeks of the procedure. In the event of such an occurrence, a search for malignancy or autoimmune disease may be warranted.
